Literature DB >> 16389311

Mouse models of Machado-Joseph disease and other polyglutamine spinocerebellar ataxias.

Veronica F Colomer Gould1.   

Abstract

Machado-Joseph disease (MJD), also called spinocerebellar ataxia type 3, is caused by mutant ataxin-3 with a polyglutamine expansion. Although there is no treatment available at present to cure or delay the onset of MJD, mouse models have been generated to facilitate the development of a therapy. In this review, the published reports on mouse models of MJD and other polyglutamine spinocerebellar ataxias are compared. Based on these studies, the following approaches will be discussed as candidate treatments for MJD: 1) interfering with the formation of the mutant ataxin-3 cleavage fragment and possibly aggregate or inclusions, 2) reducing the disease protein nuclear localization, and 3) decreasing mutant ataxin-3 expression in neurons.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16389311      PMCID: PMC1144491          DOI: 10.1602/neurorx.2.3.480

Source DB:  PubMed          Journal:  NeuroRx        ISSN: 1545-5343


  34 in total

1.  Machado-Joseph disease: cerebellar ataxia and autonomic dysfunction in a patient with the shortest known expanded allele (56 CAG repeat units) of the MJD1 gene.

Authors:  Y Takiyama; K Sakoe; I Nakano; M Nishizawa
Journal:  Neurology       Date:  1997-08       Impact factor: 9.910

2.  Expanded polyglutamine in the Machado-Joseph disease protein induces cell death in vitro and in vivo.

Authors:  H Ikeda; M Yamaguchi; S Sugai; Y Aze; S Narumiya; A Kakizuka
Journal:  Nat Genet       Date:  1996-06       Impact factor: 38.330

3.  Intranuclear inclusions of expanded polyglutamine protein in spinocerebellar ataxia type 3.

Authors:  H L Paulson; M K Perez; Y Trottier; J Q Trojanowski; S H Subramony; S S Das; P Vig; J L Mandel; K H Fischbeck; R N Pittman
Journal:  Neuron       Date:  1997-08       Impact factor: 17.173

4.  Purkinje cell expression of a mutant allele of SCA1 in transgenic mice leads to disparate effects on motor behaviors, followed by a progressive cerebellar dysfunction and histological alterations.

Authors:  H B Clark; E N Burright; W S Yunis; S Larson; C Wilcox; B Hartman; A Matilla; H Y Zoghbi; H T Orr
Journal:  J Neurosci       Date:  1997-10-01       Impact factor: 6.167

5.  Machado-Joseph disease gene product is a cytoplasmic protein widely expressed in brain.

Authors:  H L Paulson; S S Das; P B Crino; M K Perez; S C Patel; D Gotsdiner; K H Fischbeck; R N Pittman
Journal:  Ann Neurol       Date:  1997-04       Impact factor: 10.422

6.  Regional and cellular expression of the Machado-Joseph disease gene in brains of normal and affected individuals.

Authors:  K Nishiyama; S Murayama; J Goto; M Watanabe; H Hashida; S Katayama; Y Nomura; S Nakamura; I Kanazawa
Journal:  Ann Neurol       Date:  1996-11       Impact factor: 10.422

Review 7.  Machado-Joseph disease.

Authors:  L Sudarsky; P Coutinho
Journal:  Clin Neurosci       Date:  1995

8.  SCA1 transgenic mice: a model for neurodegeneration caused by an expanded CAG trinucleotide repeat.

Authors:  E N Burright; H B Clark; A Servadio; T Matilla; R M Feddersen; W S Yunis; L A Duvick; H Y Zoghbi; H T Orr
Journal:  Cell       Date:  1995-09-22       Impact factor: 41.582

9.  Recovery from polyglutamine-induced neurodegeneration in conditional SCA1 transgenic mice.

Authors:  Tao Zu; Lisa A Duvick; Michael D Kaytor; Michael S Berlinger; Huda Y Zoghbi; H Brent Clark; Harry T Orr
Journal:  J Neurosci       Date:  2004-10-06       Impact factor: 6.167

10.  RNAi suppresses polyglutamine-induced neurodegeneration in a model of spinocerebellar ataxia.

Authors:  Haibin Xia; Qinwen Mao; Steven L Eliason; Scott Q Harper; Inês H Martins; Harry T Orr; Henry L Paulson; Linda Yang; Robert M Kotin; Beverly L Davidson
Journal:  Nat Med       Date:  2004-07-04       Impact factor: 53.440

View more
  2 in total

1.  Glutamatergic Synapse Dysfunction in Drosophila Neuromuscular Junctions Can Be Rescued by Proteostasis Modulation.

Authors:  Anushka Chakravorty; Ankit Sharma; Vasu Sheeba; Ravi Manjithaya
Journal:  Front Mol Neurosci       Date:  2022-07-15       Impact factor: 6.261

Review 2.  Deubiquitylating enzymes and disease.

Authors:  Shweta Singhal; Matthew C Taylor; Rohan T Baker
Journal:  BMC Biochem       Date:  2008-10-21       Impact factor: 4.059

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.